ALLO Stock Analysis: Buy, Sell, or Hold?
ALLO - Allogene Therapeutics, Inc. Common Stock
$2.09
-0.01 (-0.48%)
▼
5d:
+1.95%
30d:
+14.84%
90d:
+6.63%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ALLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ALLO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ALLO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALLO is currently trading at $2.09, which is considered extended relative to its 30-day fair value range of $1.79 to $2.07.
Technical Outlook: Technically, ALLO is in a downtrend. Immediate support is located at $1.92, while resistance sits at $2.23.
Market Sentiment: ALLO scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+330.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALLO is in a downtrend. Immediate support is located at $1.92, while resistance sits at $2.23.
Market Sentiment: ALLO scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+330.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.79 -
$2.07
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 330.6% below Wall St target ($9.00)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.79 -
$2.07
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.92
Resistance Level
$2.23
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.98
Wall Street Target
$9.00
(+330.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 23, 2026 11:24 AM ET
Data refreshes hourly during market hours. Next update: 12:24 PM
Data refreshes hourly during market hours. Next update: 12:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Annie Yoshiyama
SELL
9586 shares
2026-04-21
Benjamin Machinas Beneski
SELL
2867 shares
2026-03-31
Benjamin Machinas Beneski
SELL
4835 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
